Literature DB >> 34717897

Phytochemicals modulate pancreatic islet β cell function through glucagon-like peptide-1-related mechanisms.

Wanfang Zheng1, Linghuan Li1, Hanbing Li2.   

Abstract

Glucagon-like peptide-1 (GLP-1) receptor-based therapies have been developed and extensively applied in clinical practice. GLP-1 plays an important role in improving glycemic homeostasis by stimulating insulin biosynthesis and secretion, suppressing glucagon activity, delaying gastric emptying, and reducing appetite and food ingestion. Furthermore, GLP-1 has positive effects on β-cell function by promoting β-cell proliferation and neogenesis while simultaneously reducing apoptosis. Here, we summarize possible mechanisms of action of GLP-1 upon pancreatic islets as well as describe phytochemicals that modulate pancreatic islet β cell function through glucagon-like peptide-1-related mechanisms. Together, this information provides potential lead compound candidates against diabetes that function as GLP-1 receptor-based pharmacotherapy.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Agonist; Allosteric modulator; Boschnaloside (PubChem CID: 155942); Diabetes mellitus; Fucoidan (PubChem CID: 92023653); Geniposide (PubChem CID: 107848); Genistein (PubChem CID: 5280961); Glucagon-like peptide-1; Myricetin (PubChem CID: 5281672); Phytochemical; Puerarin (PubChem CID: 5281807); Quercetin (PubChem CID: 5280343); [6]-Gingerol (PubChem CID: 442793)

Mesh:

Substances:

Year:  2021        PMID: 34717897     DOI: 10.1016/j.bcp.2021.114817

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  2 in total

1.  Novel 6-Methoxy-3,4-dihydro-1H-isoquinoline Compounds for Treating Diabetes.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-05-25       Impact factor: 4.632

2.  Mitigation of MAFLD in High Fat-High Sucrose-Fructose Fed Mice by a Combination of Genistein Consumption and Exercise Training.

Authors:  Chaheyla R St Aubin; Amy L Fisher; Jose A Hernandez; Tom L Broderick; Layla Al-Nakkash
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-23       Impact factor: 3.249

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.